Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma Plc LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 55.00 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
45.00 65.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -24.13 -18.90 228
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 55.00 GBX

Verona Pharma (VRP) Latest News

More Verona Pharma News
Verona Pharma Investors    Verona Pharma Takeover Rumours

Verona Pharma (VRP) Discussions and Chat

Verona Pharma Forums and Chat

Date Time Title Posts
10/6/202114:35Verona Pharma: Developing first in class drugs for respiratory diseases1,436
30/10/201808:41Still time to look at Verona Pharma (VRP)-
01/8/201810:42Verona Pharma (VRP) One to Watch -
16/2/201517:30Verona Pharma with Charts & News11,549
24/11/201112:54verona pharma173

Add a New Thread

Verona Pharma (VRP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Verona Pharma trades in real-time

Verona Pharma (VRP) Top Chat Posts

Verona Pharma Daily Update: Verona Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker VRP. The last closing price for Verona Pharma was 55p.
Verona Pharma Plc has a 4 week average price of 0p and a 12 week average price of 0p.
The 1 year high share price is 112.50p while the 1 year low share price is currently 46.50p.
There are currently 414,278,294 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Verona Pharma Plc is £227,853,061.70.
haff1: now this is what we've been waiting for for years.....this is very good news for VRP..
timbo003: A bit of good news released this morning (for a change).....
haff1: NASDAQ has recold highs...but VRP falls! surprize there then......
approach3: Any idea why H & L are not giving a current price here.
drradcliffe: Yes I know. Once they get Ensifentrine through the phase 3 trials, approved by the FDA and launched commercially, we'll still do very well. The stock will be valued at a much higher figure than it ever would have been on the London market. I've only stuck with the investment because the phase 2 clinical trial results look good enough for a commercial product. I don't think the price will do much this year, but next year should see serious growth if everything goes according to plan. Like anyone else who converted from VRP, I'm still up 50%.
approach3: Has anyone any views on how todays news will effect the share price.
shakin not stirred: I believe a few investors do not understand the possible implications.Anyway as the majority of directors do not live in the UK it will have to adhere to paying what I believe will be a much bigger Tax bill in the USA and not as attractively incentivised as in the UK.If Biden is elected and implements his planned pharma higher taxes then Verona will be alot worse of by my reckoning. Anyway looks like Verona Pharma will have failed again imo.Hilarious when those investors stateside realise the possible future implications they will sell now before it drops like a stone and buy back in after the elections in November and hold alot more shares for their buck.Reckon this will be down to $4.50 in the states before election day.Painful for anyone buying in the high $5's like recently.Wait till the next accounts are released and the US investors see the cash burn from just the management salaries nevermind "other expenses". Maybe they could not even afford to keep the UK offices and hence used the excuse of leaving AIM. Strange when so much research has been done in Manchester and Kings college london.You can see why so many chief medical officers have left Verona Pharma and it says alot that the share price has been decimated on the AIM and see no reason why the same will not happen on the Nasdaq imo.Buying vrna at $3 may be an appropriate price point if the same pattern occurs.
shakin not stirred: Well Timbo you will probably be purchasing more as the price has only been worked higher so those in the latest fund raise can exit hence the big price drop in the USA today. The Yanks will eventually cotton on to the pattern that this share price follows. Sell high and buy low. This is to be traded to get any money from your investment.I too will top up at placement price.When we have lost so many chief medical officers it really tells the true picture. The share price even at £1 should be lunacy but so often the market has it correct more often than the investors and the share price is where it is due to poor direction and lost opportunities. This company is great if you are on the payroll otherwise totally uninspiring in all they do. Glad you are still about Timbo. Expecting that we will both get the chance to top up below the placing price this side of Christmas.
shakin not stirred: Not surprising to see this has dropped back as was expected as fund raise is now completed and no news due to middle of next year so retrace fully expected to go back to price of 45p which was the placing price. Very low placing price and II's that took part in first global funding must be laughing at the opportunity to buy at this price. The closer this gets to the shares being admitted the further this share price will drop Resting point 45p if we are lucky we may see this hold at 50p till some results next year. I should have sold and bought back in. Tempted to even at this point as would make financial sense. A very long wait here and better opportunities lie in gold and silver mining companies at the minute. Big sells and reckon that any would be investors will wait until this gets much closer to the placing price of 45p. Should be there by end of month at this rate
shakin not stirred: By the time we get the update someone might wish to ask what JAk thinks of the share price and if the drug is all he reckons as no sign of Significant shareholder value. If so then in which decade should we expect to see it. Why do they reward themselves disproportionately to the share price performance and is he aware no one is currently in profit yet he has continued to recruit at will and no further advancement to our lead drug if not only drug enisfenterine in my opinion. Does he see 40p as representing significant shareholder value. Please someone ask the question. Ask Jak at what share price level does this need to reach for them to call it a day and put shareholders out of their misery. All the above my opinion and can anyone post a Nasdaq share price and how that equates at the exchange rate to the share price on aim. Sorry for being slightly as have forgotten how many shares are worth the other as seems an age ago
Verona Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Verona Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210615 00:46:17